Chronic lymphocytic leukaemia: clinical-aetiological findings in 66 patients and their families

Hereditary Cancer in Clinical Practice

Marcel Zwahlen³  Jacqueline Estoppey¹  Patrick F Maurer²  Walter Weber¹ 

[1] Clinical Cancer Etiology Unit, Heuberg 16, CH-4051 Basel, Switzerland;Urological University Clinic of Both Basel, CH-4410 Liestal, Switzerland;ISPM, University of Bern, CH-3012 Bern, Switzerland

关键词: familial cancer;    familial leukaemia;    chronic lymphocytic leukaemia;    CLL;   

Others  :  810705
DOI  :  10.1186/1897-4287-5-4-210

 received in 2007-08-02, accepted in 2007-09-30,  发布年份 2007

【 摘 要 】

Background

Little is known about the aetiology of chronic lymphocytic leukaemia (CLL). The family medical history is a "genomic tool" capturing interactions of genetic susceptibility, shared environment and common behaviours.

Methods

A cohort of 66 consecutives patients with CLL (probands) was studied in a medical oncology practice (W.W.) from 1981 until 2005. A German version of the NCI medical history questionnaire for cancer aetiology was used. Familial clustering analysis was done by comparing the proportion of specific tumours in the first degree relatives of the CLL practice cohort with corresponding proportions of population-based cancer registry data.

Results

18 (41%) male and 5 (23%) female CLL probands had multiple malignancies, e.g. 2 meningiomas, 7 and 19 years after diagnosis of CLL. 46 (12%) first degree relatives had malignancies with an excess of CLL. Other conspicuous familial associations are CLL with malignancies of the upper GI tract (oesophagus, stomach) and of the nervous system.

Conclusion

1. Chronic lymphocytic leukaemia clusters in some families like any other disease. Predisposition genes should be searched. 2. Cancer prevention and early detection should be continued in CLL patients because of their longevity and high risk for multiple malignancies. 3. The overrepresentation of upper GI malignancies in first degree relatives of CLL patients calls for targeted oesophago-gastroscopy screening studies.

   

【 参考文献 】

• [1]Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH: Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994, 86:1600-1008.
• [2]Hemminki K, Vaittinen P: National database of familial cancer in Sweden. Genet Epidemiol 1998, 15:225-236.
• [3]Weber W, Estoppey J, Stoll H: Familial cancer diagnosis. Anticancer Res 2001, 21:3631-3636.
• [4]Emery J, Murphy M, Lucassen A: Hereditary cancer – the evidence for current recommended management. Lancet Oncol 2000, 1:9-16.
• [5]Yoon PW, Scheuner MT, Khoury MJ: Research priorities for evaluating family history in the prevention of common chronic diseases. Am J Prev Med 2003, 24:128-135.
• [6]Chiorazzi N, Rai KR, Ferrarini M: Chronic lymphocytic leukemia. N Engl J Med 2005, 352:804-815.
• [7]Mulvihill JJ, Miller RW, Fraumeni JF Jr, eds: Genetics of Human Cancer. Raven Press, New York; 1977:489-493.
• [8]Muir C, Waterhouse J, Mach T, Powell J, Whelan S, eds: Cancer Incidence in Five Continents. Volume III. IARC, Lyon; 1976::374-375.
• [9]Parkin DM, Muir CC, Whelan SL, Gao YT, Terlay J, Powell J: Cancer Incidence in Five Continents. Volume VI. IARC, Lyon; 1992::748-749.
• [10]Greene MH, Wilson J: Second cancer following lymphatic and hematopoietic cancers in Connecticut, 1935–82. Natl Cancer Inst Monogr 1985, 68:191-217.
• [11]Hisada M, Biggar RJ, Greene MH, Fraumeni JF Jr, Travis LB: Solid tumors after chronic lymphocytic leukemia. Blood 2001, 98:1979-1981.
• [12]Wiernik PH: Second neoplasms in patients with chronic lymphocytic leukemia. Curr Treat Options Oncol 2004, 5:215-223.
• [13]Yuille MR, Matutes E, Marossy A, Hilditch B, Catovsky D, Houlston RS: Familial chronic lymphocytic leukemia: a survey and review of published studies. Br J Haematol 2000, 109:794-799.
• [14]Casey R, Brennan P, Becker N, Boffetta P, Cocco P, Domingo-Domenech E, Foretova L, Nieters A, de Sanjose S, Staines A, Vornanen M, Maynadie M: Influence of familial cancer history on lymphoid neoplasms risk validated in the large European case-control study epilymph. Eur J Cancer 2006, 42:2570-2576.
• [15]Rawstron AC, Yuille MR, Fuller J, Cullen M, Kennedy B, Richards SJ, Jack AS, Matutes E, Catovsky D, Hillmen P, Houston RS: Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. Blood 2002, 100:2289-2291.
• [16]Summersgill B, Thornton P, Atkinson S, Matutes E, Shipley J, Catovsky D, Houlston RS, Yuille MR: Chromosomal imbalances in familial chronic lymphocytic leukemia: a comparative genomic hybridisation analysis. Leukemia 2002, 16:1229-1232.
• [17]Ng D, Toure O, Wei MH, Arthur DC, Abbasi F, Fontaine l, Marti GE, Fraumeni JF Jr, Goldin LR, Caporaso N, Toro JR: Identification of a novel chromosome region, 13q21.33–q22.2, for susceptibility genes in familial chronic lymphocytic leukemia. Blood 2007, 109:916-925.
• [18]Novak AJ, Grote DM, Ziesmer SC, Kline MP, Manske MK, Slager S, Witzig TE, Shanafelt T, Call TG, Kay NE, et al.: Elevated serum B-lymphocyte stimulator levels in patients with familial lympho-proliferative disorders. J Clin Oncol 2006, 24:983-987.
• [19]Nenova IS, Karnolski IN, Mateva NG, Sotirova KN: Familial study of chronic lymphocytic leukemia: aggregation of different malignant processes in families with individuals affected with chronic lymphocytic leukemia. Folia Med (Plovdiv) 2006, 48:11-16.